Cargando…
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma
OBJECTIVE: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. MATERIALS & METHODS: HRQoL was assessed at baseline and day 1 of each cycle using the European Organization for Research and Treatment of Cancer 30-item core quali...
Autores principales: | Gounder, Mrinal, Abdul Razak, Albiruni R, Gilligan, Adrienne M, Leong, Hoyee, Ma, Xiwen, Somaiah, Neeta, Chawla, Sant P, Martin-Broto, Javier, Grignani, Giovanni, Schuetze, Scott M, Vincenzi, Bruno, Wagner, Andrew J, Chmielowski, Bartosz, Jones, Robin L, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Riedel, Richard F, Attia, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344436/ https://www.ncbi.nlm.nih.gov/pubmed/33855868 http://dx.doi.org/10.2217/fon-2021-0284 |
Ejemplares similares
-
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
por: Gounder, Mrinal M., et al.
Publicado: (2022) -
Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma
por: Thirasastr, Prapassorn, et al.
Publicado: (2022) -
Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma
por: Garg, Manoj, et al.
Publicado: (2016) -
Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down‐regulation
por: Zuco, Valentina, et al.
Publicado: (2021) -
Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
por: Dolph, Michael, et al.
Publicado: (2021)